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INTRODUCTION 
 
An in vitro S30-based Escherichia coli expression system (“Transcription-Translation”, 
or “TX-TL”) has been developed as an alternative prototyping environment to the cell for 
synthetic circuits [1-5].  Basic circuit elements, such as switches and cascades, have been 
shown to function in TX-TL, as well as bacteriophage assembly [2, 6]. Circuits can also 
be prototyped from basic parts within 8 hours, avoiding cloning and transformation steps 
[7]. However, most published results have been obtained in a “batch mode” reaction, 
where factors that play an important role for in vivo circuit dynamics – namely protein 
degradation and protein dilution – are severely hindered or are not present. This limits the 
complexity of circuits built in TX-TL without steady-state or continuous-flow solutions 
[8-10].  However, alternate methods that enable dilution either require extra equipment 
and expertise or demand lower reaction throughput.  
 
We explored the possibility of supplementing TX-TL with ClpXP, an AAA+ protease 
pair that selectively degrades tagged proteins [11], to provide finely-tuned degradation. 
The mechanism of ClpXP degradation has been extensively studied both in vitro and in 
vivo [12-15]. However, it has not been characterized for use in synthetic circuits – metrics 
such as toxicity, ATP usage, degradation variation over time, and cellular loading need to 
be determined. In particular, TX-TL in batch mode is known to be resource limited [16], 
and ClpXP is known to require significant amounts of ATP to unfold different protein 
targets [17, 18]. We find that ClpXP’s protein degradation dynamics is dependent on 
protein identity, but can be determined experimentally. Degradation follows Michaels-
Menten kinetics, and can be fine tuned by ClpX or ClpP concentration. Added purified 
ClpX is also not toxic to TX-TL reactions. Therefore, ClpXP provides a controllable way 
to introduce protein degradation and dynamics into synthetic circuits in TX-TL. 
 
 
RESULTS AND DISCUSSION 
 
There are two methods to supplement ClpXP into TX-TL – by expressing the proteins off 
of plasmid DNA or by adding purified protein. We first attempted to express both ClpX 
and ClpP off of DNA, and found that ClpX when expressed was able to degrade 
fluorescent ssrA-tagged reporters at a rate independent of ClpP concentration (data not 
shown). However, expressing ClpX posed two difficulties: degradation was rate-limited 
and time-delayed based on production rate of ClpX, and the load of ClpX expression 
reduced the expression of other synthetic circuits. To avoid these problems, we tried to 
purify a N-terminal His-tagged version of ClpX using a standard Ni-NTA procedure; 
however, we found that this version of ClpX lost activity after the purification procedure 
when stored in a previously developed glycerol-free buffer compatible with TX-TL [7]. 
We hypothesized that a linked-hexametric form previously developed would be more 
stable in solution [13].  With the His-tagged linked-hexameric N-terminal deletion form 
of ClpX, we were able to retain activity (Fig. 1ab). We refer to this as the ClpX form 
hereafter. To quantify degradation rates, we also purified fluorescent proteins with and 
without –ssrA tags (Fig. 1c). 
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Figure 1. Purification of clpXdeltaNLinkedHexamer (“ClpX”) and fluorescent proteins. a) ClpX with 
a His6 tag is purified in a Ni-NTA column and run on denaturing SDS-PAGE gel. b) Size excluded 
chromatography of elute product on a Superdex 200 10/300 column, with a functionality test of active 
species. B5-B11 are fractions combined for forward use. c) Three fluorescent proteins (deGFP, mRFP, 
Venus), with or without ssrA tags, with a His6 tag are purified in a Ni-NTA column and run on denaturing 
SDS-PAGE gel. Last column is active, purified fractions combined for forward use. 
 
 
We first verified the ability of purified ClpX to selectively degrade ssrA-tagged versions 
of deGFP, mRFP, and Venus over non-tagged versions (Fig. 2). ClpX is selective for 
ssrA-tagged versions over non-ssrA tagged versions, and has a degradation rate 
dependent on protein identity. This is similar to findings in vitro, where ClpX is known to 
have different unfolding rates and ATP hydrolysis rates depending on the target difficulty 
[17, 19]. We also determined the concentration dependence of ClpX to degradation rate 
and throughput (Fig. 3ab). Initially, we made a simple Michelis-Menten model: 
 
 𝑑 𝐺𝐹𝑃𝑑𝑡 =   −𝑘!"# 𝐶𝑙𝑝𝑋𝑃 𝐺𝐹𝑃𝐺𝐹𝑃 +   𝐾!  
 𝐶𝑙𝑝𝑋𝑃 = min  ( 𝐶𝑙𝑝𝑋 , 𝐶𝑙𝑝𝑃 ) 
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Figure 2. Degradation of deGFP, Venus, and mRFP by added ClpX.  400 nM of purified ClpX is 
combined with approximately 5 µM of purified fluorescent proteins with and without ssrA degradation tags 
in TX-TL. 
 
 
We set Km to 1.1 µM, kcat to 0.9 min-1 based on previously published parameters [14], and 
estimated initial (native) concentrations of 20 nM ClpX and of 250 nM ClpP in TX-TL 
extract. We also ran a TX-TL experiment varying added ClpX concentrations from 0 nM 
to 400 nM. Comparing the modeling data to the experimental data, ClpXP degradation 
closely follows Michaelis-Menten kinetics as described. We also determined 
concentration dependence of ClpX to Venus-ssrA and mRFP-ssrA, and then plotted the 
degradation rate vs. time (Fig. 3c). Since the degradation rate changes over time as the 
concentration of substrate decreases, we plotted degradation rate vs. added ClpX 
concentration at t = 16.5 min, which we took as an initial degradation rate (Fig. 3d). In 
this figure, the dependence of fluorescent reporter to added ClpX concentration can be 
clearly discerned, with a saturation point between 200-400 nM of additional ClpX added 
to the system, suggesting a rate-limiting native ClpP concentration. The decreased 
degradation rate of Venus-ssrA relative to deGFP-ssrA and mRFP-ssrA can also be seen. 
Based on this figure, additional ClpX is able to increase deGFP-ssrA degradation rates by 
5-fold, mRFP-ssrA degradation rates by 4.2-fold, and Venus-ssrA degradation rates by 
1.8-fold. 
 
We additionally tried to supplement TX-TL with ATP and Mg, based on the known 
heavy usage of ClpX for protein unfolding (500 ATP per titin I27 subunit, ~100 aa) [19]. 
With 200 nM of added ClpX in TX-TL, there was a clear effect on the degradation of 
Venus-ssrA over deGFP-ssrA and mRFP-ssrA, indicating that at working concentrations 
of proteins likely achievable in a typical TX-TL reaction ATP concentration was not rate-
limiting except on hard-to-degrade proteins (Fig. 4).  
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Figure 3. Dependence of degradation on ClpX concentration. A) Shown to the left is a Michaelis-
Menten kinetics model of degradation of fluorescent GFP-ssrA over time, using Km 1.1 µM, kcat 0.9 min-1, 
similar to literature values [14]. Added ClpX is varied from 400nM to 0nM.  Showing to the right is 
experimental data demonstrating similar results as modeling data for deGFP-ssrA. B) Degradation rate of 
deGFP-ssrA, Venus-ssrA, and mRFP-ssrA over time with varied ClpX concentration. At the arrow is t = 
16.5 min. C) Degradation rate plotted at t = 16.5 min as a function of added ClpX, for both ssrA tagged and 
non-ssrA tagged fluorescent proteins. 
 
 
In order for supplemented ClpX to be a useful tool for controlled protein degradation, 
either the addition of ClpX or the ClpX storage buffer must not be toxic to expression of 
proteins off of DNA in TX-TL. We diagnosed this by diluting purified ClpX into a TX-
TL reaction driving the production of deGFP off of a strong promoter, and saw no effect 
at saturating ClpX levels to DNA expression (Fig. 5). We also verified that ATP was not 
rate-limiting to ClpXP degradation and DNA expression by treating the degradation of 
mRFP-ssrA as a “background process” running during a TX-TL reaction producing 
deGFP (Fig. 6). As 10 µM of mRFP-ssrA is approaching the maximum protein 
concentration producible by TX-TL, this result suggests that ATP is at a saturating level 
in a typical TX-TL reaction. However, we did not test the combination of a difficult-to-
degrade protein such as Venus-ssrA combined with the expression of saturating amounts 
of mRFP, which would support this conclusion. 
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We also explored increasing the amount of ClpP in a saturated ClpX TX-TL reaction to 
verify that ClpP was a limiting reagent. For simplicity, we expressed ClpP off of a strong 
promoter instead of adding purified amounts of ClpP. In the main extract used, “eZS6” 
derived from an ExpressIQ strain (New England Biolabs), ClpP was able to marginally 
increase degradation of deGFP-ssrA in the presence of 200 nM of ClpX (Fig. 7a). 
However, the ability to increase degradation was more pronounced in an alternate extract, 
“e8”, made from a BL21 Rosetta2 strain (Novagen) (Fig. 7b). This indicates that ClpXP 
degradation dynamics can be different depending on strain and on preparation, which 
could vary the amount of native ClpX or ClpP already present.  
  
CONCLUSION 
 
We explored the use of supplementing the ClpXP system inherent in TX-TL with 
purified ClpX protease to provide fine-tunable degradation to run synthetic dynamic 
circuits. ClpXP degradation closely follows Michaelis-Menten kinetics, but has varying 
degradation rates depending on substrate. Degradation can also be controlled by ClpX 
concentration, allowing for up to 5-fold increased degradation rates over non-tagged 
variants. Degradation does not limit the running of synthetic circuits when purified ClpX 
is added, and rates can be further increased by adding ClpP when ClpX reaches saturated 
conditions between 200-400 nM. 
 
While ClpXP provides tunable degradation, it may not be an ideal substitute for protein 
dilution, as degradation is neither linear nor stepwise. However, due to the fact that 
degradation closely follows Michaelis-Menten kinetics, degradation can be included in a 
“biological breadboard”-type model [20] to predict amounts needed to implement circuit 
dynamics. This can be easily done for fluorescent proteins, but may require indirect 
assays for other commonly used circuit components such as activators or repressors. 
However, once substrate degradation rates are characterized supplementing ClpX is easy 
to accomplish and fairly predictable when adjusting for concentration. 
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Figure 4. Dependence of degradation on added ATP and Mg. A) With added ClpX set to 200 nM, 
degradation of fluorescent ssrA tagged proteins is plotted as a function of time and additional ATP and Mg 
added to each reaction. B) Degradation rate at t = 16.5 min from above data is plotted as a function of 
additional ATP and Mg. 
 
 
 
 
Figure 5. Toxicity of added ClpX to TX-TL expression. A plasmid expressing deGFP off of a strong 
promoter-UTR is added to a TX-TL reaction at 1 nM, and endpoint expression after 8 hours is plotted as a 
function of added, purified ClpX protein.  
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Figure 6. Effect of background degradation processes to TX-TL expression. A plasmid expressing 
deGFP off of a strong promoter-UTR is added to a TX-TL reaction at 1nM. In the same reaction, purified 
mRFP-ssrA is being degraded by 200 nM of added ClpX. No additional ATP or Mg is added to the 
reaction. 5 difference concentrations of mRFP-ssrA are tested. Both remaining mRFP-ssrA and deGFP 
expression are measured in real time. 
 
  
 
 
Figure 7. Effect of ClpP expression on degradation. A) In eZS6 extract, a plasmid expressing ClpP off 
of a strong promoter-UTR is added to a TX-TL reaction at varying concentrations in the presence of 200 
nM of added purified ClpX. Degradation of deGFP-ssrA is plotted versus time. B) The same experiment as 
A), but in a different extract. 
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MATERIALS AND METHODS 
 
Cell-free extract preparation and execution: 
Preparation and execution of TX-TL was according to previously described protocols [1], 
with a modification in strain to ExpressIQ (New England Biolabs) and lysis according to 
work by Jewett et al. (personal communication).  This resulted in extract “eZS6” with 
conditions: 9.9 mg/mL protein, 9.5 mM Mg-glutamate, 95 mM K-glutamate, 0.33 mM 
DTT, 1.5 mM each amino acid except leucine, 1.25 mM leucine, 50 mM HEPES, 1.5 
mM ATP and GTP, 0.9 mM CTP and UTP, 0.2  mg/mL tRNA, 0.26 mM CoA, 0.33 mM 
NAD, 0.75 mM cAMP, 0.068 mM folinic acid, 1 mM spermidine, 30 mM 3-PGA, 2% 
PEG-8000. Only “eZS6” is used to prevent extract-to-extract variation, except in the final 
figure where “e8” prepared from BL21 Rosetta2 (Novagen) using previously described 
protocols [1] was used.  Reactions were conducted in 15 µL in a 384-well plate (Nunc) at 
29°C, and read in a Synergy H1/MF or H4 plate reader (Biotek). Settings used were: 
deGFP, 485 nm/515 nm gain 61; Venus, 505 nm/ 535 nm, gain 61; mRFP, 580 nm/ 610 
nm, gain 100.  
 
Protein purification: 
For fluorescent proteins eGFP, mRFP, and Venus and variants eGFP-ssrA, mRFP-ssrA, 
and Venus-ssrA, coding sequences were cloned into a T7-lacO inducible vector 
containing a N-terminus His6 tag using standard techniques and propagated in a BL21-
DE3 strain (New England Biolabs). Proteins were purified following a similar protocol as 
in [7], but were grown in TB broth in lieu of LB broth, induced with 1 mM IPTG (final 
concentration), and selected for a band between 25 kDa – 35 kDa corresponding to the 
fluorescent protein in question. Fluorescent proteins were further processed in a Supradex 
20 10/300 column to select for pure, active proportions, and flash-frozen at -80°C in a 
storage buffer consisting of: 50 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM 
EDTA, 2% DMSO shown previously to be amenable to usage in TX-TL [7]. Final 
concentrations were: deGFP-ssrA, 164.8 µM; deGFP, 184.8 µM; mRFP-ssrA, 185.6 µM; 
mRFP, 170.6 µM; Venus-ssrA, 87.9 µM; Venus, 147.5 µM. 
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For ClpX, a monomeric N-terminal deletion variant Flag-clpXdeltaNLinkedHexamer-
His6 was used [13] (Addgene #22143), as purifying the wildtype with a N-terminal His-
tag using general Ni-NTA purification techniques resulted in a loss of activity. We 
followed a Ni-NTA purification procedure listed in [12], followed by Supradex 20 
10/300 and functional testing for pure, active proportions above 250 kDa. Active 
proportions were flash frozen in the same buffer used for fluorescent proteins. Final 
concentration of ClpX was 1.95 µM.  
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